Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note released on Saturday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

ADXS stock opened at $0.03 on Friday. The company’s 50 day moving average is $0.04 and its 200 day moving average is $0.17. The stock has a market cap of $1.15 million, a price-to-earnings ratio of 0.00 and a beta of 1.81. Ayala Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.